Endocrine evaluation of hirsutism  by Mihailidis, John et al.
International Journal of Women's Dermatology 1 (2015) 90–94
Contents lists available at ScienceDirect
International Journal of Women's DermatologyEndocrine evaluation of hirsutismJohn Mihailidis, MD a,1, Racha Dermesropian, MD a,1, Pamela Taxel, MD a,
Pooja Luthra, MD, FACE a, Jane M. Grant-Kels, MD b,⁎
a University of Connecticut Medical Center, Division of Endocrinology and Metabolism, Department of Medicine, Farmington, CT
b University of Connecticut Medical Center, Department of Dermatology, Farmington, CT
a b s t r a c ta r t i c l e i n f o⁎ Corresponding author.
E-mail address: grant@uchc.edu (J.M. Grant-Kels).
1 Co-ﬁrst authors: J. Mihailidis and R. Dermesropian.
http://dx.doi.org/10.1016/j.ijwd.2015.04.003
2352-6475/© 2015 The Authors. Published by Elsevier Inc. on
licenses/by-nc-nd/4.0/).Article history:
Received 15 November 2014
Received in revised form 31 March 2015
Accepted 16 April 2015Hirsutism is deﬁned as excessive terminal hair growth in amale pattern in females. It typically affects 5 to 10% of
reproductive-agewomen. Excessive hair growth canoften cause signiﬁcant psychological and emotional distress.
As a result, hirsutism is a common presenting complaint to healthcare professionals, including dermatologists, as
women search for cosmetic and medical solutions to their problem. Hirsutism results from excess production of
androgens, often from ovarian or adrenal sources. It is typically associated with a metabolic syndrome like poly-
cystic ovarian syndrome (PCOS), but can be idiopathic ormedication-induced. This article provides an endocrine
perspective for the evaluation and management of hirsutism.
©2015TheAuthors. PublishedbyElsevier Inc. onbehalf ofWomen'sDermatologic Society. This is anopenaccess article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
True hirsutism is medically deﬁned as excessive terminal hair
appearing in a male pattern in females (Ferriman and Gallwey, 1961;
Hartz et al., 1979; McKnight, 1964). Hirsutism affects between 5 and 10%
of reproductive-age women in the general population and can often be a
sign of conditions of androgen excess. Excessive hair growth can cause a
tremendous amount of emotional distress for patients (Barth et al., 1993;
Sonino et al., 1993). Feelings of self-consciousness often stem from what
is considered the “ideal hair pattern”withinour culture and society. For ex-
ample, in theUnited States, “ideal” is considered as no terminal hair except
for the scalp, eyebrows, eyelashes, and pubis (Loriaux, 2012). Using this
deﬁnition, a large number of normal women would be considered to
have hirsutism. The terms hirsutism and hypertrichiosis are sometimes
used interchangeably. However, hypertrichiosis is deﬁned as excessive
hair growth, terminal or vellus, in non-androgen-dependent areas of the
body. Hypertrichiosis can be congenital or acquired.
This text will outline an appropriate evaluation of a patient
with hirsutism.
Pathogenesis
Hair growth is regulated by a number of local and systemic factors,
growth factors, cytokines, and sex steroids (Azziz et al., 2000; Danilenko
et al., 1996; Harmon and Nevins, 1993; Moore et al., 1991; Peus and
Pittelkow, 1996; Philpott et al., 1994). Thyroid and growth hormones
have also been shown to alter hair-growth patterns. Sex steroids, partic-
ularly androgens, play an important role in the type of hair that formsbehalf of Women's Dermatologic Sociand howhair is distributed over the human body. As androgen levels in-
crease during puberty, vellus follicles in speciﬁc areas develop into ter-
minal hair (Akiyama et al., 1996). Additionally, androgens act to
increase sebum secretion, resulting in increased oiliness of the skin
and hair. Finally, androgens prolong the anagen phase of body hair
and shorten the anagen phase of scalp hair (Ebling, 1986; Randall,
1994; Rosenﬁeld, 2005).
Hirsutism results from an interaction between androgen levels and the
sensitivity of the hair follicle to androgens (Rosenﬁeld, 2005). The level
and duration of exposure to androgens, the local 5-alpha-reductase activ-
ity, and the intrinsic sensitivity of the hair follicle to androgen action deter-
mine whether vellus hair is converted to terminal hair (Hawryluk and
English, 2009). Excess androgen levels lead to increased terminal hair
growth in most androgen-sensitive sites (e.g., upper lip, chin, chest, back,
and upper abdominal area). Although androgen excess underlies most
cases of hirsutism, there is only amodest correlation between the quantity
of hair growth and androgen levels (Azziz et al., 2000).
Causes of hirsutism
Hirsutism is often the initial, and possibly only, sign of an underlying
androgen disorder. Therefore, understanding the various causes of hir-
sutism will help guide the evaluation of these patients (Table 1).
Polycystic ovarian syndrome
Polycystic ovarian syndrome (PCOS) is the most common cause of
hirsutism in women. Hirsutism typically develops at puberty. Charac-
teristics of PCOS includemenstrual irregularities or infertility, insulin re-
sistance (in the form of diabetes or metabolic syndrome), clinical signs
of androgen excess (including acne and hirsutism), and biochemicalety. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Causes of Hirsutism.
Polycystic ovarian syndrome
Congenital adrenal hyperplasia
- classical
- nonclassical
Cushing’s disease
Ovarian tumors
Adrenal tumors
- Adenoma
- Carcinoma
Growth hormone excess
Insulin resistance
Stromal hyperthecosis
Medications
- Cyclosporine
- Testosterone injections, creams, patches
- Progestins
- Diazoxide
- Minoxidil
- Phenytoin
- Danazol
- Glucocorticoids
- Anabolic steroids
Information from Loriaux L. (2012). An Approach to the Patient with Hirsutism. J Clin
Endocrinol Metab 97(9):2957-2968
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ries is not necessary for the diagnosis of polycystic ovarian syndrome.
The exact cause of PCOS is uncertain, but it is thought to bemultifacto-
rial. PCOS develops when the ovaries are stimulated to produce excessive
amounts of androgens. This can occur through excessive luteinizing hor-
mone (LH) release or hyperinsulinemia. Elevated insulin levels increase
gonadotrophin releasing hormone (GnRH) pulse frequency, LH over
follicle-stimulating hormone dominance, and androgen production, and
decrease sex hormone-binding globulin (SHBG) (Mayo Clinic Staff, 2011).
Idiopathic hirsutism
Approximately half of all womenwithmild hirsutismhave idiopath-
ic hirsutism (Reingold and Rosenﬁeld, 1987). It is usually a diagnosis of
exclusion.Women diagnosed with idiopathic hirsutism often have nor-
mal serumandrogen concentrations, nomenstrual irregularities, and no
identiﬁable cause of hirsutism (Azziz et al., 2000; Glickman and
Rosenﬁeld, 1984; Moore et al., 1983).
Congenital adrenal hyperplasia
Congenital adrenal hyperplasias are a group of autosomal recessive
disorders affecting enzymes responsible for cortisol production. Classic
congenital adrenal hyperplasia can present in three forms: 21-
hydroxylase deﬁciency, 11-hydroxylase deﬁciency, and 3-beta hy-
droxysteroid dehydrogenase deﬁciency. Of these, 21-hydroxylase
deﬁciency is the most common (Loriaux, 2012). These disorders
are usually recognized at birth or in early infancy, as they tend to
present with androgen excess, hirsutism, genital ambiguity, and
cortisol deﬁciency.
Nonclassical or late-onset form of this disorder is milder and de-
velops in late childhood or early adulthood. Women affected with this
condition typically present with hirsutism and occasionally primary
amenorrhea or infertility, but they lack evidence of cortisol deﬁciency.
Symptoms can often resemble PCOS. The nonclassic form is almost al-
ways due to 21-hydroxylase deﬁciency leading to increase production
of both 17-hydroxyprogesterone and androstenedione.
Ovarian tumors
Androgen-secreting tumors make up only 5% of all ovarian tu-
mors. They cause hirsutism, typically later in life, and tend to prog-
ress more rapidly. Serum testosterone levels are greater than 150 to
200 ng/dL (Friedman et al., 1985; Meldrum and Abraham, 1979;
Moltz et al., 1984).
Adrenal tumors
These are rare causes of hyperandrogenism. Most of these tumors
are adrenal carcinomas and typically cause hypercortisolism and excess
androgen secretion (dihydroepiandrostenedione [DHEA] andDHEA sul-
fate [DHEA-S]). Therefore, patients typically present with rapid onset of
Cushing's syndrome and hyperandrogenism.
Cushing's disease
Cushing’s disease is typically a result of an adrenocorticotrophic
hormone-secreting pituitary adenoma resulting in excessive secretion of
not only cortisol, but also adrenal androgens, by the adrenal gland. Hirsut-
ism is a common symptom of this disorder alongwithweight gain, hyper-
tension, roundingof the face, abdominal striae, and irregularmenstruation.
Hyperthecosis
Hyperthecosis occurs when an area of luteinization develops along
with stromal hyperplasia in the ovary. The luteinized thecal cellsoverproduce androgens, more speciﬁcally testosterone, resulting in hir-
sutism and virilization. The cause is unknown.
Insulin resistance
This is a condition inwhich cells fail to respondnormally to insulin. Se-
vere hyperinsulinemia causes increased GnRH pulse frequency, increased
androgen production, and decreased SHBG, resulting in elevated levels of
free or active testosterone (Mayo Clinic Staff, 2011). Women who have
severe insulin resistance or hyperinsulinemia often develop hirsutism.
Medications
There are many drugs that may be associated with the development
of hirsutism (Table 1).
Evaluation
Mostwomenwith hirsutism typically present to their physician’s of-
ﬁce with cosmetic concerns regarding excessive hair growth. Many of
these women may have underlying conditions of androgen excess.
Therefore, it is important to perform a thorough history, physical exam-
ination, and biochemical evaluation to identify any underlying endo-
crine disorders.
History
Initial questions should focus on the duration of symptoms. Recent
onset, worsening hirsutism, or onset later in life rather than near puberty
should raise suspicion for androgen-secreting tumors. Evaluation should
also focus on signs of virilization, including deepening of the voice, acne,
increased muscle mass, male pattern hair loss, and clitoromegaly.
As almost every woman with excessive androgens will have irregu-
larmenstrual cycles, obtaining an appropriatemenstrual history is vital.
Women with polycystic ovarian syndrome often present with irregular
menses. Women with regular menses may have idiopathic hirsutism.
Ethnicity should also be considered while obtaining a history. Women
of Mediterranean descent on average have greater quantities of body
hair compared with most Asian women, who have relatively little
body hair (Carmina et al., 1992).
Finally, family history of hirsutism, infertility, and obesity, along
with medication use, should be reviewed.
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When evaluating a woman with hirsutism, the Ferriman–Gallwey
(FG) score is a simple and commonly used method to quantify hair
growth (Ferriman and Gallwey, 1961). This method evaluates nine an-
drogen sensitive sites and grades them from 0 to 4 (Ferriman and
Gallwey, 1961). Scores above eight are considered abnormal in Cauca-
sian and African American females. Scores between 8 and 15 are usually
considered to be mild hirsutism, whereas scores greater than 25 indi-
cate severe hirsutism (Ferriman and Gallwey, 1961). Some limitations
of this scoring system include: (a) the variation in hair growth between
different ethnic groups; (b) failure to account for regional hirsutism;
and (c) the fact that many women may have treated their excessive
hair growth with cosmetic measures, such as chemical depilatories,
electrolysis, laser therapy, etc.
Evaluation of physical signs of insulin resistance such as acanthosis
nigricans and Cushing's syndrome (i.e., thinning of the skin, rounding
of the face, dorsal fat pad, abdominal striae, or easy bruising) is required.
Male pattern baldness, increase in muscle mass, acne, and deepening of
the voice are signs of virilization. Abdominal andpelvic exams should be
performed to look for masses and to evaluate clitoral size.
Biochemical testing
The goal behind biochemical evaluation of womenwith hirsutism is
to identify women with markedly elevated androgen levels suggestive
of androgen-secreting tumors. Serum total testosterone levels and
DHEA-S levels are usually obtained to rule out ovarian and adrenal tu-
mors, respectively.
The Endocrine Society guidelines suggest against the routine evalu-
ation of androgen levels in women with mild hirsutism. The guidelines
suggest biochemical testing only in women with moderate to severe
hirsutism, sudden onset hirsutism, or rapidly progressive hirsutism.
The guidelines also recommend further biochemical testing in evalua-
tion of hirsutismwhen associatedwith infertility, irregularmenses, cen-
tral obesity, or acanthosis nigricans (Martin et al., 2008).
Total testosterone provides the best initial evaluation of androgen
production in hirsutewomen. Direct free testosterone assays are not ac-
curate. Further evaluation of free testosterone by equilibrium dialyses
could be indicated if total testosterone is signiﬁcantly elevated. A total
testosterone level greater than 150 ng/dl warrants further investigation,
because it is suggestive of an ovarian or adrenal testosterone-secreting
tumor or ovarian hyperthecosis.
DHEA-S levels greater than 700mcg/dl raise suspicion for hormone-
secreting adrenocortical carcinoma. 17-hydroxyprogesterone levels
should be checked in women with a high likelihood of congenital adre-
nal hyperplasia, such as women with a positive family history or who
belong to high risk ethnic groups (Hispanic, Slavic, Ashkenazi Jew).
In women with menstrual abnormalities, a prolactin level should be
obtained. A 24-hour urine free cortisol exam is recommended in
women with signs of cortisol excess. A pelvic ultrasound is indicated in
women with a suspected ovarian androgen-secreting tumor. Computed
tomographyof the adrenals is recommended forwomenwith a suspected
adrenal tumor with signiﬁcant elevation in testosterone levels.
Management of hirsutism
Mild or moderate hirsutism does not always require treatment. The
2008 Endocrine Society guidelines have coined the term “patient-
important hirsutism” to emphasize the patient’s perception of the se-
verity of the condition and the importance of taking patient preference
into consideration when decision is made to initiate treatment (Martin
et al., 2008). In any case, the underlying cause of excess hair growth
should be identiﬁed when possible.
Women should be educated about cosmetic aswell as pharmacolog-
ical therapies, the possible need for long-term treatment, and thepotential side effects of the different drugs or procedures. Realistic ex-
pectations should be set for the patient at the initiation of therapy. Pa-
tients should be advised that pharmacologic therapy will likely result
in slower hair growth and less-frequent need for hair removal as op-
posed to complete elimination of hair follicles. Monitoring response to
treatment should be done by obtaining a FG score at baseline and, if pos-
sible, at every visit. The most important outcome is likely the patient’s
perception of improvement. There are no recommendations to follow
androgen levels during treatment. Treatment can be continued during
the reproductive years as long as the patient desires and should be
stopped if pregnancy is contemplated.
Oral contraceptives
Estrogen-progestin combinations are usually considered safe and
cost-effective. Their mechanism of action stems from progestin’s ability
to suppress LH production and, subsequently, ovarian androgen pro-
duction. Estrogen increases the levels of SHBG, consequently decreasing
the levels of free testosterone and other SHBG-bound androgens. Oral
contraceptives (OCPs) also inhibit adrenal androgens by interfering
with their synthesis. OCPs are usually started with a combination of
ethinyl estradiol (0.03 to 0.035 mg) in combination with a progestin
that has low androgenic or antiandrogenic properties.
Two progestinswith antiandrogenic properties, cyproterone acetate
(CPA) and drosperinone, have been compared for treatment of PCOS.
In a recent study, 52 women with PCOS were randomized to
0.035 mg of ethinyl estradiol with 2 mg of CPA or 0.03 mg of ethinyl es-
tradiolwith 3mgof drosperinone for 12months. The studydemonstrat-
ed a median decline in the total modiﬁed FG score of 35% in the CPA
group, as opposed to an 18% median decline in the drosperinone
group at 12 months (p = .035). The study concluded that OCPs with
CPA are more effective for the treatment of hirsutism in PCOS
(Kahraman et al., 2014).
Antiandrogen Therapy
Spironolactone is an aldosterone antagonist related structurally to
progestins. It competes with dihydrotestosterone (DHT) for binding an-
drogen receptors. Spironolactone also has an inhibitory effect on 5-
alpha reductase and, at doses higher than 200 mg per day, inhibits
action of various enzymes involved in androgen biosynthesis. Starting
dose is usually 50 mg twice daily, which is then increased to 100 mg
twice daily if needed. Themain side effects include hyperkalemia, irreg-
ular menses, and teratogenicity.
Finasteride is a type-2, 5-alpha reductase inhibitor. Only a partial in-
hibitory effect is anticipatedwith ﬁnasteride as it does not affect type-1,
5-alpha reductase inhibitors. Usual dose for hirsutism is 5 mg per day,
although some data suggest that a higher dose of 7.5 mg per day
might be more effective. The main side effect is the feminization of a
male fetus becauseDHT is involved in the development ofmale external
genitalia. When used in women of reproductive age, it should be used
with effective contraception.
Flutamide is a nonsteroidal antiandrogen. It blocks androgen recep-
tors, preventing the binding of DHT. Usual dose is 250 to 750 mg per
day, which is equal in efﬁcacy to spironolactone 100 mg/day or ﬁnaste-
ride 5 mg/day. Flutamide is associated with hepatotoxicity, which may
be dose dependent. As such, it is not recommended as ﬁrst- line therapy
and the lowest effective dose should be used with careful monitoring of
liver function.
Cyproterone is a 17-hydroxyprogesterone acetate derivative with
strong progestogenic effects. It competes with DHT for the androgen re-
ceptor and decreases serum LH and ovarian androgen production. It is
used at a lowdose of 2mg as the progestin part of combination oral con-
traceptives, or at a higher dose of 12.5 to 100 mg per day as monother-
apy. It is not available in the United States.
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were identiﬁed comparing antiandrogen therapy to placebo. Meta-
analysis of these trials showed that compared to placebo, antiandrogens
(spironolactone, ﬁnasteride, and ﬂutamide) signiﬁcantly reduced hirsut-
ism, lowering FG scores by 3.9 (95% CI [2.3, 5.4]), with no apparent differ-
ence among the three medications, although head-to-head comparisons
of the three antiandrogens were not performed (Sahin et al., 1998;
Swiglo et al., 2008). In a randomized control trial comparing OCPs (con-
taining low-dose cyproterone) to antiandrogens (ﬁnasteride), there was
no signiﬁcant difference in the FG score (Sahin et al., 1998).
The 2008 Endocrine Society guidelines suggest OCPs as ﬁrst-line
therapy to treat “patient-important” hirsutism. The guidelines recom-
mend against antiandrogen monotherapy unless effective contracep-
tion is used, due to teratogenic effects. In women who are not
contemplating fertility or who cannot conceive, the use of OCPs or
antiandrogens will depend on patient preference. The guidelines also
suggest against the use of ﬂutamide, given its hepatotoxicity (Martin
et al., 2008).
Insulin-sensitizing agents
Bothmetformin and thiazolidinediones have been used to attenuate
hyperinsulinemia and decrease androgen levels. The role of these med-
ications in the absence of metabolic disturbances remains controversial.
The best available evidence on metformin is based on a systematic
review of nine trials comparing metformin or troglitazone to placebo.
The study showed a modest effect on hirsutism, with a decrease in the
FG scores by 1.5.
A separate subgroup analysis of eight trials comparingmetformin to
placebo found no signiﬁcant difference (Cosma et al., 2008). The 2008
Endocrine Society guidelines suggest against the use of insulin-
lowering agents as therapy for hirsutism (Martin et al., 2008).
Other therapies
GnRH agonists inhibit gonadotropins and decrease ovarian andro-
gen production, leading to decreased hirsutism but also lower estrogen
levels. They are usually used in conjunction with low-dose estrogen–
progestin pills to eliminate the effects of estrogen deﬁciency. Weak ev-
idence suggests that GnRH therapy is more effective than placebo for
the treatment of hirsutism, but there seems to be no evidence to support
its use over OCPs or antiandrogens. The medication itself is expensive
and requires injections. The Endocrine Society guidelines suggest
against its use except in women with severe hyperandrogenemia who
do not respond to or cannot tolerate OCPs and antiandrogens (Martin
et al., 2008).
Steroids are usually used long term in women with classic 21-
hydroxylase deﬁciency. They suppress adrenal androgen production
and control hirsutism, while maintaining ovulatory cycles. Trials com-
paring glucocorticoids to antiandrogens and OCPs in women with the
nonclassic form of 21-hydroxylase deﬁciency (NCCAH) found glucocor-
ticoids to be more effective in suppressing adrenal androgens, but less
effective in controlling hirsutism (Spritzer et al., 1990).
The Endocrine Society guidelines suggest against the use of gluco-
corticoids for routinemanagement of hirsutism inwomenwithout clas-
sic or nonclassic form of congenital adrenal hyperplasia related to 21-
hydroxylase deﬁciency.
The use of glucocorticoids in women with NCCAH is suggested for
those who do not respond to or cannot tolerate OCPs or antiandrogens,
or those who seek ovulation induction (Spritzer et al., 1990).
Combination therapy
A systematic review identiﬁed ﬁve trials comparing antiandrogens
combined with OCPs versus OCPs alone. A meta-analysis of these trials
showed no signiﬁcant difference in hirsutism scores between the twotreatment groups. However, pooling of spironolactone and ﬁnasteride
comparisons revealed a signiﬁcant effect compared with OCP alone
(–1.7, 95 % CI [0.1, 3.3]) (Sahin et al., 1998). Ameta-analysis of two tri-
als comparingﬂutamide andmetformin showed signiﬁcantly lower hir-
sutism scores in patients using both medications compared to patients
on metformin alone (4.6, 95% CI [1.3, 7.9]; Swiglo et al., 2008). The
2008 Endocrine Society guidelines suggest adding an antiandrogen if
hirsutism persists after 6 months of monotherapy with OCPs alone
(Martin et al., 2008).
Topical treatment
Eﬂornithine hydrochloride 13.9% (Vaniqa) is a topical preparation
that inhibits hair growth by irreversibly inhibiting ornithine decarbox-
ylase. It does not remove hair, but rather slows hair growth. It can be
used alone or in conjunction with other therapies.
Randomized control trials have reported a more signiﬁcant hair
growth reduction when comparing a combination of laser therapy
with eﬂornithine versus laser therapy and placebo cream, especially
early in the treatment course (Hamzavi et al., 2007). The Endocrine So-
ciety guidelines suggest the addition of eﬂornithine to photoepilation
therapy in women who desire a more rapid initial response (Martin
et al., 2008).
Nonpharmacologic methods
Temporary methods
Temporary methods such as shaving, plucking, or waxing are effec-
tive, safe, and inexpensive. They can be used alone or in combination
with pharmacologic therapy.
Permanent methods
These include photoepilation (laser or intense pulsed light)
or electrolysis.
Women with hyperandrogenemia will experience hair regrowth,
and the 2008 Endocrine Society guidelines suggest concomitant use of
pharmacologic treatment to prevent recurrence (Martin et al., 2008).
Lifestyle modiﬁcations
Lifestyle modiﬁcations includingweight loss have been suggested in
the treatment of hirsutism. Ameta-analysis byMoran et al. (2011) iden-
tiﬁed four studies addressing the effect of lifestyle modiﬁcations on hir-
sutism in womenwith PCOS. Lifestyle modiﬁcations (e.g., diet, exercise,
behavioral changes, or combined treatments) showed signiﬁcant im-
provement of excess hair growth by the FG score compared with mini-
mal or no treatment (mean difference –1.19 (95% CI [–2.35, –0.03], p=
.04). The treatment group also showed a signiﬁcant difference in total
testosterone levels, weight, and waist circumference (Fig. 1).
The authors concluded that lifestyle modiﬁcations improved
hyperandrogenism inwomenwith PCOS and its clinical manifestations,
including hirsutism. Other reviews on the treatment of hirsutism have
also suggested counseling patients on smoking cessation. Smoking
could potentially interfere with the treatment of hirsutism, especially
when OCPs are being considered (Somani and Turvy, 2014).
Conclusion
Successful management of hirsutism often requires an interdisci-
plinary approach. This can often be achieved through involvement of
physicians (endocrinologists, gynecologists, dermatologists), psycholo-
gists, and cosmeticians. The goal with this multifocal approach is not
only to tackle cosmetic worries through medical therapy and mechani-
cal hair removal, but also to address the woman's concerns regarding
self-image and psychological stresses that are associated with excessive
body hair.
Hirsutism
Contraindicated?
Yes
Oral contraceptive
pills
Life style
modifications
Anti-androgen
medications
N
o
6-12 months trial
If no improvement or
moderate/severe
hirsutism
Add
Cosmetic
methods/permanent
hair reduction methods
Topical Eflornithine
Combination anti-androgen
medications
With reliable
contraception
Add
Add
Fig. 1.Management of hirsutism.
94 J. Mihailidis et al. / International Journal of Women's Dermatology 1 (2015) 90–94In summary, hirsutism is a common dermatologic complaint that is
often seen in young women of reproductive age. It can cause signiﬁcant
psychological distress. It is important for healthcare providers to under-
stand the pathophysiology as well as the appropriate evaluation of this
disorder to rule out underlying disease or tumors. Whenmedical thera-
py is used for hirsutism, the provider must educate the patient regard-
ing the usual or expected time frame of decreased hair growth. Close
follow-up for assessment and tolerance of medical therapy and efﬁcacy
is critical, as is emotional support of the patient.
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